This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
In the article titled “Utilisation Trend of Long-Acting Insulin Analogues including Biosimilars across Europe: Findings and Implications” [1], the captions of Figures 3 and 4 were incorrect. The corrected captions for Figures 3 and 4 appear below.
[figure(s) omitted; refer to PDF]
[1] B. Godman, M. Wladysiuk, S. McTaggart, A. Kurdi, E. Allocati, M. Jakovljevic, F. Kalemeera, I. Hoxha, A. Nachtnebel, R. Sauermann, M. Hinteregger, V. Marković-Peković, B. Tubic, G. Petrova, K. Tachkov, J. Slabý, R. Nejezchlebova, I. S. Krulichová, O. Laius, G. Selke, I. Langner, A. Harsanyi, A. Inotai, A. Jakupi, S. Henkuzens, K. Garuolienė, J. Gulbinovič, P. V. Bonanno, J. Rutkowski, S. Ingeberg, Ø. Melien, I. Mardare, J. Fürst, S. MacBride-Stewart, C. Holmes, C. Pontes, C. Zara, M. T. Pedrola, M. Hoffmann, V. Kourafalos, A. Pisana, R. Banzi, S. Campbell, B. Wettermark, "Utilisation Trend of Long-Acting Insulin Analogues including Biosimilars across Europe: Findings and Implications," BioMed Research International, vol. 2021,DOI: 10.1155/2021/9996193, 2021.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Copyright © 2023 Brian Godman et al. This is an open access article distributed under the Creative Commons Attribution License (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. https://creativecommons.org/licenses/by/4.0/
Details










1 Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow G4 0RE, UK; Division of Public Health Pharmacy and Management, School of Pharmacy, Sefako Makgatho Health Sciences University, Pretoria, South Africa; School of Pharmaceutical Sciences, Universiti Sains Malaysia, Penang, Malaysia
2 Chair of Epidemiology and Preventive Medicine, Medical College, Jagiellonian University, Krakow, Poland; HTA Consulting, Starowiślna Str. 17/3, 31-038 Krakow, Poland
3 Public Health Scotland, Gyle Square, 1 South Gyle Crescent, Edinburgh, UK
4 Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow G4 0RE, UK; Division of Public Health Pharmacy and Management, School of Pharmacy, Sefako Makgatho Health Sciences University, Pretoria, South Africa; Department of Pharmacology, College of Pharmacy, Hawler Medical University, Erbil, Iraq
5 Istituto di Ricerche Farmacologiche “Mario Negri” IRCCS, Milan, Italy
6 Institute of Advanced Manufacturing Technologies, Peter the Great St. Petersburg Polytechnic University, St. Petersburg, Russia; Institute of Comparative Economic Studies, Hosei University Tokyo, Japan; Department of Global Health Economics and Policy, University of Kragujevac, Serbia
7 Department of Pharmacy Practice and Policy, Faculty of Health Sciences, University of Namibia, Windhoek, Namibia
8 Department of Pharmacy, Faculty of Medicine, University of Medicine, Tirana, Albania
9 Dachverband der Österreichischen Sozialversicherungen, Kundmanngasse 21, AT-1030 Vienna, Austria
10 Faculty of Medicine, Department of Social Pharmacy, University of Banja Luka, Banja Luka, Bosnia and Herzegovina
11 Faculty of Medicine, Department of Medicinal Chemistry, University of Banja Luka, Banja Luka, Bosnia and Herzegovina; Agency for Medicinal Product and Medical Devices of Bosnia and Herzegovina, 78000 Banja Luka, Bosnia and Herzegovina
12 Faculty of Pharmacy, Department of Social Pharmacy and Pharmacoeconomics, Medical University of Sofia, Sofia, Bulgaria
13 State Institute for Drug Control, Prague, Czech Republic
14 Department of Medical Biophysics, Faculty of Medicine in Hradec Králové, Charles University, Simkova 870, 500 03 Hradec Králové, Czech Republic
15 State Agency of Medicines, Nooruse 1, 50411 Tartu, Estonia
16 Wissenschaftliches Institut der AOK (WIdO), Rosenthaler Straße 31, 10178 Berlin, Germany
17 Department of Health Policy and Health Economics, Eotvos Lorand University, Budapest, Hungary
18 Syreon Research Institute and Semmelweis University, Center of Health Technology Assessment, Budapest, Hungary
19 Faculty of Pharmacy, UBT Higher Education Institute, Pristina, Kosovo
20 Independent Consultant, Riga, Latvia
21 Department of Pathology, Forensic Medicine and Pharmacology, Institute of Biomedical Sciences, Faculty of Medicine, Vilnius University, Vilnius, Lithuania
22 Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow G4 0RE, UK; Department of Health Services Management, University of Malta, Valletta, Malta
23 HTA Consulting, Starowiślna Str. 17/3, 31-038 Krakow, Poland
24 Medicines Committee, Oslo University Hospitals, Oslo, Norway
25 Faculty of Medicine, Public Health and Management Department, “Carol Davila” University of Medicine and Pharmacy Bucharest, 050463 Bucharest, Romania
26 Health Insurance Institute, Miklosiceva 24, SI-1507 Ljubljana, Slovenia
27 Pharmacy Services, Greater Glasgow and Clyde (NHS GGC), Glasgow, UK
28 NHS Lothian, Edinburgh, UK
29 Drug Department, Catalan Health Service, Gran Via de les Corts Catalanes, 08007 Barcelona, Spain; Department of Pharmacology, Therapeutics and Toxicology, Universitat Autònoma de Barcelona, Barcelona, Spain
30 Drug Department, Catalan Health Service, Gran Via de les Corts Catalanes, 08007 Barcelona, Spain
31 NEPI-Nätverk för Läkemedelsepidemiologi, Stockholm, Sweden
32 National Organization for the Provision of Healthcare Services (EOPYY), Athens, Greece
33 Department of Global Public Health, Karolinska Institutet, Stockholm, Sweden
34 Centre for Primary Care and Health Services Research, School of Health Sciences, University of Manchester, Manchester M13 9PL, UK; NIHR Greater Manchester Patient Safety Translational Research Centre, School of Health Sciences, University of Manchester, Manchester, UK
35 Department of Pharmacy, Disciplinary Domain of Medicine and Pharmacy, Uppsala University, Uppsala, Sweden